Academic Journals Database
Disseminating quality controlled scientific knowledge


Author(s): Nirmal K. Karki | Azhar Ahmed | Rita Charde | Manoj Charde | Bhushan Gandhare

Journal: International Journal of Biomedical and Advance Research
ISSN 2229-3809

Volume: 2;
Issue: 1;
Start page: 69;
Date: 2011;
Original page

Keywords: Novel drug delivery | Antifungal | fungal infections

The number of fungi causing systemic disease is growing and the number of systemic diseases caused by fungi is increasing. The currently available antifungal agents for the treatment of systemic mycoses include polyene antibiotics (Amphotericin B), fluoropyrimidine (Flu cytosine), and Nystatin andazole group of drugs (Ketoconazole, Fluconazole, and Itraconazole). Novel drug delivery systems for antifungal therapy, based on the type of formulation are classified as Liposomes Nanocochleates, Nanospheres, Carbon Nanotubes, Doubled layered Mucoadhesive Tablets, Mucoadhesive Thermo Sensitive Pronged release gels, and Parenteral Micro emulsions. Amphotericin B is the only fungicidal agent available and is the ‘goldstandard’ for the treatment of most of the systemic mycoses. The three currently available lipid formulations are Amphotericin B Lipid Complex (ABLC), Amphotericin B Colloidal Dispersion (ABCD) and Liposomal Amphotericin B (L‐AmB). Nystatin and ketoconazole are also commercially available as liposomes. Novel Drug delivery systems for antifungal therapy, aiming at reducing the side effects and maximizing the antifungal activity have added a new dimension to the treatment of fungal infections. Without fungi we would not have bread, beer, wine or antibiotics, but more importantly without the nutrient recycling and plant nutrition provided by fungi - we probably could not survive at all.
Affiliate Program      Why do you need a reservation system?